Most frequent complaints reported(multiple complaints per patient are possible)

Adverse effect may be due to disease and/or other underlying condition and medication/treatment may not be causative factor




DRUG RATING DETAILS (RANK BASED ON RATINGS OF SIMILAR DRUGS; SEE TABLE AT BOTTOM)


Drug Brand Name Yervoy
Drug Substance/Generic Name ipilimumab
Number of Patients Complaining 8,115
Serious Reactions to Substance 7,679
Non Serious Reactions to Substance 1,436
Substance Not Effective Complaints 0
At-Ray Ratio (NSR/SR); Safety indicator, higher is safer 0.19
PP Ratio (Patients Complaining/Not Effective), higher is more effective 0
Drug Rating = PP Ratio* At-Ray Ratio 1.34

Summary (from Wikipedia)


Ipilimumab (trade name Yervoy) is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows CTLs to function. Ipilimumab was approved by the U.S. FDA in 2011 for the treatment of melanoma, a type of skin cancer. It is undergoing clinical trials for the treatment of non-small cell lung carcinoma (NSCLC), small cell lung cancer (SCLC), bladder cancer and metastatic hormone-refractory prostate cancer. The concept of using anti-CTLA4 antibodies to treat cancer was first developed by James P. Allison while he was director of the Cancer Research Laboratory at the University of California, Berkeley. Clinical development of anti-CTLA4 was initiated by Medarex, which was later acquired by Bristol-Myers Squibb. As of 2013 the cost was $120,000 for a course of treatment. For his work in developing ipilimumab, Allison was awarded the Lasker Award in 2015.

Indications and Usage (from FDA label)


1 INDICATIONS AND USAGE YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: •Treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older). (1.1) •Adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) 1.1 Unresectable or Metastatic Melanoma YERVOY is indicated for the treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older) [see Clinical Studies (14.1)]. 1.2 Adjuvant Treatment of Melanoma YERVOY is indicated for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy [see Clinical Studies (14.2)].

Copyright for images below belongs to manufacturer mentioned in label, presented for information only


Monoclonal antibodies
(19) Similar Drugs to Yervoy ; Comparison Table Below
(Best drugs have high rating/ranking,high safety ratio and high effectivity ratio)
Brand Name (Click for details) Active Ingredient Drug ATC Class Price Found (US $) OVERALL
Drug Rating

Yervoy FORUM: Comments, Support, Doubts? Please sign on to disqus(www.disqus.com) and post below

Forum